The first regenerative medicine based on stem cells could be filed for approval in Europe later this year, bringing the groundbreaking medical technology a step closer to reality. In my article, the European Medicines Agency (EMEA) has said that it had been informed about the "intent of a European manufacturer to submit the first application for marketing authorization for a stem cell-based product." For many investors in pharmaceutical companies, stem cells remain off the radar screen for now after early excitement about the science was followed by delays and disappointments in the clinic, but pharmaceutical companies pioneering the technology have not given up and a growing number of large pharmaceutical companies are also starting to dip their toes in the water.